International Journal of Keratoconus and Ectatic Corneal Diseases

Register      Login

VOLUME 6 , ISSUE 1 ( January-June, 2017 ) > List of Articles


Two Years’ Experience in Keratoconus Treatment using Collagen Cross-linking

Dimitrii Dementiev, Maria Sysoeva, Anna Shipunova

Citation Information : Dementiev D, Sysoeva M, Shipunova A. Two Years’ Experience in Keratoconus Treatment using Collagen Cross-linking. Int J Kerat Ect Cor Dis 2017; 6 (1):11-13.

DOI: 10.5005/jp-journals-10025-1136

License: CC BY 3.0

Published Online: 01-12-2011

Copyright Statement:  Copyright © 2017; The Author(s).



To evaluate safety, efficacy, and stability of cross-linking (CLX) procedure as a method for keratoconus treatment in the I and II stage of disease.

Materials and methods

Twenty eyes of 15 patients (13 males, 2 females, average age 31 years) with keratoconus I stage (13 eyes) and II stage (2 eyes) (by Krumeich classi­fication) were treated by CLX procedure, using riboflavin Medio Cross for standard CLX); riboflavin Medio Cross TE for transepithelial CLX was used to treat keratectasia after previous keratorefractive surgery; in all the cases UV CBM X linker (Vega, CSO) was used. The study included evaluation of uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA) pre- and postoperative, pachymetry (central cornea thickness) (Visante OCT, Zeiss) pre- and postoperative, total astigmatism pre- and postoperative, using keratotopography (Atlas, Zeiss). Diagnosis and analysis have been performed at the International Center for Ophthalmology in Moscow, Russian ­Federation, since 2012 to 2014 years. Follow-up period was from 1 to 24 months.


Average UCVA preoperative was 0.4 (Decimal), and average BCVA was 0.64. Average UCVA postoperative was 0.49; average BCVA was 0.66. Total astigmatism preoperative was 2.81 D; total astigmatism postoperative 2.80 D. Central cornea thickness (CCT) preoperative 454 mkm; CCT post­operative 447 mkm.


Cross-linking indicated safety, stability, and efficacy for treatment of I and II stage keratoconus at the end of follow-up period. Cross-linking is not effective in the treatment of II and III stage of disease. Further study is required.

How to cite this article

Dementiev D, Sysoeva M, Shipunova A. Two Years’ Experience in Keratoconus Treatment using Collagen Cross-linking. Int J Kerat Ect Cor Dis 2017;6(1):11-13.

  1. Corneal collagen cross-linking with riboflavin and ultraviolet – a light in progressive keratoconus. Ophthalmologe 2015 Feb;112(2):140-147.
  2. Safety of high-intensity corneal collagen crosslinking. J Cataract Refract Surg 2014 Aug;40(8):1337-1340.
  3. Trans epithelial corneal collagen crosslinking for progressive keratoconus: 6 months follow up. Cont Lens Anterior Eye 2014 Dec;37():6438-441.
  4. Increased corneal hysteresis after corneal collagen crosslinking: a study based on applanation resonance technology. JAMA Ophthalmol 2014 Dec;132(12):1426-1432
  5. Mutations in the zinc finger protein gene, ZNF469, contribute to the pathogenesis of keratoconus. Invest Ophthalmol Vis Sci 2014 Aug5;55(9):5629-5635.
  6. Polymorphisms of the apoptosis-related FAS and FAS ligand genes in keratoconus and Fuchs’ endothelial corneal dystrophy. Tohoku J Exp Med 2014234(1):17-27.
  7. J Ophthalmol 2014;2014:719205.
  8. Accelerated versus standard corneal collagen crosslinking combined with same day phototherapeutic keratectomy and single intrastromal ring segment implantation for keratoconus. Br J Ophthalmol 2015 Feb;99(2):155-159.
  9. Three-year follow-up of posterior chamber toric phakic intraocular lens implantation for the correction of high myopic astigmatism in eyes with keratoconus. Br J Ophthalmol 2015 Feb;99(2):177-183.
  10. Sterile keratitis after combined riboflavin-UVA corneal collagen cross-linking for keratoconus. Eye (Lond) 2014 Nov;28(11):1297-1303.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.